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Atrial fibrillation (AF) is common in ICU patients and is associated with a two- to fivefold increase inmortality.This paper provides
a reappraisal of the management of AF with a special focus on critically ill patients with haemodynamic instability. AF can cause
hypotension and heart failure with subsequent organ dysfunction. The underlying mechanisms are the loss of atrial contraction
and the high ventricular rate. In unstable patients, sinus rhythm must be rapidly restored by synchronised electrical cardioversion
(ECV). If pharmacological treatment is indicated, clinicians can choose between the rate control and the rhythm control strategy.
The optimal substance should be selected depending on its potential adverse effects. A beta-1 antagonist with a very short half-life
(e.g., esmolol) is an advantage for ICU patients because the effect of beta-blockade on cardiovascular stability is unpredictable in
those patients. Amiodarone is commonly used in the ICU setting but has potentially severe cardiac and noncardiac side effects.
Digoxin controls the ventricular response at rest, but its benefit decreases in the presence of adrenergic stress. Vernakalant converts
new-onset AF to sinus rhythm in approximately 50% of patients, but data on its efficacy and safety in critically ill patients are
lacking.
1. Introduction
Atrial fibrillation (AF) is the most common arrhythmia in
patients hospitalised in intensive care units (ICUs) and is
associated with increased morbidity and mortality [1–6].
In light of the improved understanding of the underlying
pathophysiology, novel therapeutic options, and recently
published guidelines for AF, this paper provides a reappraisal
of the topic with a special focus on the management of AF in
critically ill patients with haemodynamic instability.
2. Materials and Methods
A search of the PubMed database and a review of bibli-
ographies from selected articles was performed to identify
original data relating to this topic. Articles were scruti-
nised regarding their study design, population evaluated,
interventions, outcomes, and limitations. A special focus
was on the literature available from critically ill patients.
However, if such information was lacking, references from
non-ICU patients were included in this narrative review.
When evidence-based recommendations were not available
at all personal recommendations were incorporated in this
report (and highlighted accordingly) to assist the clinicians
in the management of critically ill patients with AF.
3. Results and Discussion
3.1. Definition and Clinical Manifestation. AF is a supraven-
tricular arrhythmia characterized by disorganized atrial
depolarisations without effective atrial contractions. If AF
terminates spontaneously, it is defined as paroxysmal. When
AF is sustained beyond seven days or is terminated with
electrical or pharmacological cardioversion it is defined as
persistent. If a conversion in sinus rhythm cannot be achieved,
AF is defined as permanent [5].
In critically ill patients, untreated AF can cause hypoten-
sion (mean arterial pressure < 65mmHg), myocardial
ischemia, and heart failure (pulmonary edema, cardiogenic
shock) with subsequent tissue hypoxia (SvO2 < 65%, lactate
> 2.0mmol/l) and organ dysfunction (encephalopathy, acute
kidney injury with urine output < 0.5mL/kg/h and liver
dysfunction).The underlyingmechanisms of these complica-
tions are the loss of atrial contraction and the high ventricular
rate, which both impair the ventricular filling. The loss of
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the atrial kick is particularly detrimental in patients with
diastolic dysfunction, such as left ventricular hypertrophy of
any cause. Left atrial pressure increases, causing pulmonary
venous hypertension and subsequent pulmonary edema
with dyspnea. When stroke volume deteriorates, cardiogenic
shock develops [7]. In addition, the high heart rate and the
secondary elevation of end-diastolic ventricular pressure
increase the myocardial oxygen demands, precipitating
acute myocardial ischemia. Uncontrolled tachycardia for the
duration of days to weeks may cause tachycardia-induced
myocardial dysfunction (tachycardiomyopathy) leading to
severe systolic heart failure, which is potentially reversible
after appropriate treatment [8, 9].
3.2. Diagnostic Evaluation. AF is diagnosed by a 12-lead
electrocardiogram (ECG), typically when a lack of 𝑃-waves,
high-frequency fibrillation waves at rates of 350–600/min,
and an irregular ventricular response (absolute arrhythmia)
are observed. The ventricular rate in untreated patients
with normal atrioventricular conduction is typically between
100 and 160 bpm, but normo- and bradycardic ventricular
response rates are possible. The initial ECG may provide
important additional information on myocardial ischemia,
left-ventricular hypertrophy, or conduction disorders. When
the differentiation of narrow-complex tachycardia is chal-
lenging, 6mg of adenosine pushed intravenously can termi-
nate a reentry tachycardia or unmask atrial flutter and AF
[10]. Of note, adenosine can precipitate ventricular tachycar-
dia in preexcitation syndromes (e.g. Wolff-Parkinson-White)
by rapid anterograde conduction of AF via the accessory
pathway [11]. After cardiac surgery, an atrial lead ECG
from the pacemaker wire can be helpful. The evaluation of
symptoms and haemodynamic consequences is the next step
[1]. If AF is accompanied by acute chest pain, dyspnea, arterial
hypotension, and/or cardiogenic shock, immediate action is
required (see below). Transthoracic echocardiography, chest
radiography, and electrolyte and serologic tests for thyroid
function are required to identify the underlying cause of
the AF [12]. In cardiac surgery patients, transthoracic or
transesophageal echocardiography may be necessary to rule
out pericardial effusion, a common trigger for AF in the early
postoperative phase.
3.3. Epidemiology. Advanced age is the biggest risk factors
for developing AF. The incidence and prevalence rises with
age (>60 years: 1%; >80 years: 5–15%) [13–18]. AF occurs in
patients with cardiac disorders (hypertensive heart disease,
coronary artery disease, valvular heart disease, pericarditis,
congenital heart disease and acquired cardiomyopathies) as
well as in patients with no apparent cardiac abnormalities
(lone AF) [5]. Many noncardiac diseases (thyroid disorders,
pulmonary diseases, and alcohol overconsumption) are also
associated with AF [19, 20]. Acute illness and surgery are
associated with increased rates of AF. The incidence of new-
onset AF in critically ill patients is 6–20% [21–23]. In the
subgroup of patients with sepsis, the incidence of new-onset
AF correlates with the severity of sepsis; up to half of the
patients with septic shock experience new-onset AF [24].
In cases with acute coronary artery disease, AF occurs in 6–
21% of patients [25]. The highest incidence is observed in
patients after open heart surgery, in particular mitral valve
surgery and coronary artery bypass graft surgery, with doc-
umented rates reaching 30–40% [26, 27]. The peak incidence
of AF occurs during the first 2–4 days after cardiac surgery
[26]. Overall, AF is associated with cardioembolic events and
heart failure, longer hospital stays, and reduced quality of life
aswell as a two- to fivefold increasedmortality [21–23, 26, 28].
3.4. Underlying Mechanisms. The complex pathophysiologi-
cal mechanisms of AF have been reviewed extensively [1–6,
29]. To better understand the various treatment options, some
basic elements of AF are summarised below. Reentry of exci-
tation wavefronts has long been considered the main mech-
anism of AF. However, intensive research during the recent
decades has revealed an interaction between the initiation
triggers and maintenance factors of AF. Table 1 summarises
the promoters of AF and what specific treatments, if any, they
are amenable to [5, 26, 29–32]. Clearly, these promoters of AF
are different in critically ill patients compared to outpatients.
Any heart disease or cardiac surgery involving sutures on the
atria can induce structural remodelling of the atria, which
results in inflammation, myocyte alteration, and tissue fibro-
sis, all of which promote AF. A few minutes after the onset of
AF, an electrical remodelling process involving ion channel
function and intracellular calcium homeostasis is stimulated,
leading to a shortening of the refractory periods of atrial
cardiomyocytes and contributing to the persistence of AF
[7, 33]. Within days, alterations to the intracellular calcium
homeostasis cause contractile remodelling, dysfunction, and
further dilatation of the atria [8, 9, 33]. Increased sympathetic
tone and systemic inflammation also play a central role in
maintaining AF [10, 34]. Inflammation may lead to atrial
myocarditis with subsequent electrical and structural atrial
changes, resulting in the initiation andmaintenance of AF [11,
35]. BecauseAF triggersAF, paroxysmalAFmight progress to
persistent and permanent AF [1, 36]. Finally, an origin of AF
has been localised in themyocardial sleeves of the pulmonary
veins, opening the door to new ablation techniques [12,
37–41]. However, the complex mechanisms leading to this
ectopic activity with bursts of rapid discharge are not yet fully
understood.
3.5. Management of Patients with Haemodynamic Instability.
The initial management of patients with haemodynamic
instability includes the restoration of an adequate perfusion
pressure with, depending upon the aetiology of AF, admin-
istration of fluids, vasopressors, and/or inotropes. Special
attention should be addressed to sedation and analgesia,
which ensure patient comfort and reduce the incidence of
harmful sympathetic activation, and a sufficient oxygen
supply of the myocardium must be guaranteed.
3.5.1. Electrical Cardioversion (ECV). In patients with acute
chest pain, dyspnea, or haemodynamic instability, the sinus
rhythm must be rapidly restored by synchronised ECV
(Figure 1). Compared to the success rate of 90% in outpatients
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Table 1: Modifiable promoters of atrial fibrillation.
Mechanism Etiology Specific treatment options
Myocardial stretch (atrial
hypertension, atrial dilatation, reduced
contractility)
Fluid overload
Acute mitral insufficiency
Mitral stenosis
Fluid removal (restrictive fluid administration,
diuretics, renal replacement therapy)
Intra-aortic balloon pump; cardiac surgery
Valvuloplasty
Inappropriate oxygen delivery to the
myocardium
Myocardial ischemia
Hypovolemia
Anemia
Revascularization
Fluid challenge
Transfusion of red blood cells
Electrolyte disturbances (risk factors:
diuretics, dialysis)
Hypokalemia
Hypomagnesemia
Substitution of potassium (goal K+ 4.5–5.5mmol/L)
Substitution of magnesium (goal Mg++ >1.0mmol/L)
Systemic and local inflammation
Heart-lung machine
Sepsis
Myocarditis
Steroids; off-pump cardiosurgical techniques
Antimicrobial therapy
Immunosuppression
Adrenergic overstimulation Inotropic supportStress (pain, anxiety)
Reduction of inotropes
Sedation; analgesia; betablockers
Endocrine disorder Elevated thyroid hormonesPheochromocytoma
Betablockers; thyreostatic drugs
Alpha- and betablockers
Various Hypothermia Correction of hypothermia
Newly diagnosed atrial fibrillation
Step 1:
1st clinical assessment
Hemodynamic unstable?
Severe symptoms? Yes
Yes
Yes
Yes
Yes
Yes
Urgent
cardioversion
Step 2:
Start rate control
Rapid conversion in
sinus rhythm?
sinus rhythm?
Optimization and
followup
Optimization and
followup
Optimization and
followup
Optimization and
followup
Step 3:
2nd clinical assessment
Rate control achieved?
Light symptoms?
Step 4:
Evaluate strategy switch
AF >48h or uncertain?
No anticoagulation?
Exclude atrial
thrombi (TEE)
Step 5:
Start rhythm control
Rapid conversion in
Step 6:
3rd clinical assessment Adequate hemodynamics?
No
Advanced ICU
management
Figure 1: Management algorithm. Legend: ICU intensive care unit. Algorithm modified from [2, 4].
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Table 2: Frequently used intravenous antiarrhythmic substances in the ICU.
Substance Dosing Half-life Commentary
Esmolol
1.0mg/kg in boluses of 10–20mg iv, followed by
continuous infusion (start with
0.05mg/kg/min, increase dose every 30
minutes if necessary)
7–10min
Good efficacy in high adrenergic state. Positive
effect on cardiovascular comorbidities. Consider
negative inotropic effects
Diltiazem 0.25mg/kg iv over 2 minutes, followed bycontinuous infusion (10–15mg/h) if necessary 2–4 h
Longer half-life as esmolol. No beta-blocking
effects. Consider negative inotropic effects
Amiodarone
150–300mg iv, followed by a continuous
infusion (900–1200mg daily) up to 0.1 g/kg
Maintenance dose 200mg daily
20–100 d
Good efficacy, safe in patients with structural
heart disease. Extreme long half-life up to 80 days.
Consider extracardiac side effects
Digoxin 0.25–0.5mg iv every 4–8 h up to 1mg, followedby maintenance dose of 0.25mg daily 20 h–6 d
Positive inotropic effect. Reduce dose in renal
dysfunction. Check digoxin plasma levels to avoid
toxicity
[13–18, 42], the conversion rate is much lower in critically
ill patients undergoing urgent cardioversion, with published
success rates as low as 30% [5, 43–46]. Pretreatment with
antiarrhythmic drugs facilitates ECV and reduces immediate
recurrences [19, 20, 47, 48]. Chest wall impedance, left atrial
size, and duration of AF are inversely related to success
rate. Prior to ECV, patients should receive sedation and
analgesia. Endotracheal intubation is required in patients at
risk of aspiration. Anterior-posterior electrode positioning
and biphasic waveforms provide higher success rates than
lateral electrode positioning and monophasic waveforms
[21–23, 42]. In postoperative cardiosurgical patients, for
whom impedance is high and electrodes are often placed
unfavourably due to wound dressing and chest tubes, we
recommend a single shock of 200 Joules to increase the
success rate [24, 49]. A previous study demonstrated that a
high initial energy reduces the incidence of tachyarrhythmic
complications [25, 50]. Particular care must be taken to
preserve the wound dressings and to avoid the nipples.
If repeated ECV is applied, the synchronisation mode has
to be switched on before every use, as this mode usually
switches off after every discharge to allow immediate defib-
rillation if necessary. In patients with pacemakers or internal
cardioverter/defibrillators (ICD), internal overdrive pacing
and/or cardioversion may be attempted by the cardiologists
to restore the sinus rhythm. If this is not possible, the external
electrodes should be placed at least 8 cm from the aggregate.
After cardioversion, the device should be checked to ensure
normal function.
In patients with life-threatening symptoms, ECV is indi-
cated even if the presence of an atrial thrombus cannot
be excluded. In stable patients with AF lasting more than
48 h, a transesophageal echocardiography to exclude an atrial
thrombus is recommended [26, 27, 51]. Alternatively an ade-
quate anticoagulation regimen of 3 weeks before cardiover-
sion is recommended [6]. After successful cardioversion the
anticoagulation should be continued for at least 4 weeks to
prevent cardioembolic complications due to atrial stunning
[6, 26]. If ECVwas not successful, pharmacological treatment
is indicated as described below. Similarly, an antiarrhythmic
treatment is usually required temporarily to maintain sinus
rhythm after successful ECV.
3.6. Management of Hemodynamic Stable Patients
3.6.1. Rate versus Rhythm Control. Clinicians can choose
between a rate control and a rhythm control strategy. The
rate control approach toleratesAFbut controls the ventricular
response rate to improve the ventricular filling and avoid
a tachycardiomyopathy. It is the treatment of choice in
patients with permanent AF or in oligosymptomatic patients
(Figure 1). Rate control can be accomplished with beta-
blockers, calcium channel blockers (diltiazem, verapamil),
digoxin, or amiodarone. 24 h telemetry should confirm that
the target heart rate of less than 110 bpm at rest has been
achieved [21–23, 26, 28, 52]. Some patients may experience
clinical improvement only after the restoration of sinus
rhythm (rhythm control strategy), which can be achieved by
ECV and/or drugs (see Figure 1). However, several trials in
outpatients failed to show a benefit of this strategy compared
to rate control only [53, 54] even in patients with congestive
heart failure [55]. The lack of a survival benefit in the rhythm
control arm was probably caused by the inefficacy of current
antiarrhythmic drugs and their adverse effects.
3.6.2. Pharmacological Options. A multitude of substances
are licensed for the pharmacologic treatment of AF, but only
a few are indicated in the ICU setting (Table 2). Because the
literature does not provide conclusive results on the optimal
pharmacologic treatment of AF for ICU patients, clinicians
should choose the optimal substance depending on its poten-
tial adverse effects [56]. Before starting an antiarrhythmic
treatment, clinicians should optimise all concurring factors
[56–58]: electrolyte derangements (potassium, magnesium)
should be corrected to upper-normal levels. Particularly
magnesium is an effective, cheap andwell-tolerated treatment
option for AF [3, 59–63].
We recommend to start with substances with a low risk
profile and short half-life, such as betablockers (see below),
and to escalate to other substance classes such as amiodarone
only in cases of contraindications or inefficacy of the initial
treatment. Generally, intravenous substances are preferred
because of their faster onset and more reliable action.
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Selective beta-1 receptor antagonists have negative chron-
otropic, dromotropic, and bathmotropic effects, slowing
heart rate, delaying conduction in the atrioventricular node,
and reducing myocardial excitability, respectively. Beta-
blockers are therefore the initial treatment of choice for a rate
control strategy. Adverse effects include the negative inotrope
activity on themyocardium as well as vasodilatation [64] that
can potentially worsen haemodynamics. Hence, a drug with
a short half-life is recommended for ICU patients, for whom
the effect of beta-blockade on cardiovascular stability is
unpredictable. Our choice is esmolol which is eliminated by
unspecific esterases and hydrolases resulting in a very short
half-life of 7–10 minutes [65]. When esmolol treatment is
initiated, we typically repeat intravenous esmolol injections
of 10–20mg to reach a dose of 1mg/kg within a few minutes
to assess its haemodynamic effects. If the mean arterial
pressure remains above 60mmHg, a continuous infusion is
started at a rate of 0.05mg/kg/min and is further increased in
30-minute intervals according to clinical needs. In patients
with oral beta-blockers, therapy should be continued as it
significantly reduces the risk of AF up to 40%, particularly
in the postoperative phase [1, 60, 66–68].
Amiodarone is commonly used in the ICU setting for
the treatment of AF. First of all, it has less negative inotropic
effects compared to beta-blockers and calciumchannel block-
ers [69]. Secondly, amiodarone is safer for patients with
structural heart disease compared to class Ic antiarrhythmic
agents, such as flecainide [3]. Amiodarone is a multichannel
blocker with inhibiting effects on adrenergic receptors and
potassium and calcium channels. It is a highly lipophilic
substance with a very large distribution volume and an
extremely long half-life [43, 45]. While a single dose of 150–
300mg of amiodarone is enough to achieve pharmacological
conversion to sinus rhythm in some patients, the majority of
patients require long-term therapy. Therefore, a loading dose
of 0.1 g/kg is required in the first 7–10 days, which can be
administered intravenously or orally. Thereafter, a daily oral
maintenance dose of 200mg is recommended. Importantly,
amiodarone has potential severe adverse effects [70]. Prolon-
gation of the QT interval is typical, but torsade de pointes
are uncommon (<0.5%) [71]. Hypo- and hyperthyroidism are
the most common extracardiac side effects of amiodarone
(>20%); thus, the thyrotropin (TSH) and free thyroid hor-
mone (fT4, fT3) levels should be checked before treatment
and every six months thereafter. Photosensitivity, corneal
deposits, and neurological side effects are also frequent, while
pulmonary and hepatic toxicity are rare but potentially life-
threatening adverse effects of amiodarone.
Digoxin inhibits the sodium-potassium pump, increasing
the calcium availability to the contractile apparatus [72].
Digoxin controls the ventricular response through direct
action on the atrioventricular node and by a centrally
mediated vagal stimulation. Despite its efficacy in controlling
resting heart rates, it is not a converter, and its benefit
decreases with adrenergic stress, limiting its efficacy in crit-
ically ill patients. On the other hand, the positive inotropic
effect of digoxin may be beneficial for patients with heart
failure. The plasma half-life ranges from 20 to 50 hours in
patients with normal kidney function and increases up to
4–6 days in patients with end-stage renal disease [72]. In
addition, drug interactions may reduce digoxin clearance
and electrolyte disturbances, such as hypokalemia, hypo-
magnesemia, and hypercalcemia, and exacerbate digoxin
toxicity. In critically ill patients, for whom a rapid control
of heart rate is desired, we administer 0.25mg digoxin
intravenously every 4 to 8 hours up to a cumulative dose
of 1.0 to 1.5mg, followed by a maintenance dose of 0.25mg
once daily. In patients with impaired kidney function, the
maintenance dose must be reduced (0.125mg daily for a
creatinine clearance of 60–90mL/min and 0.125 every other
day for a creatinine clearance of 30–60mL/min) [72]. To
avoid adverse events, regular surveillance of electrolytes and
signs of digitalis toxicity (see below) are recommended.
Serum digoxin levels (measured at least 6 hours after the last
dose) may be helpful to corroborate the diagnosis of toxicity
but are not recommended for routine use [73]. Digoxin can
cause a broad spectrum of ventricular and supraventricular
arrhythmias, such as ectopic rhythms, pacemaker depression,
or conduction abnormalities. Visual disturbances (blurred
vision, flashing lights, halos, and green or yellow patterns),
nausea, and vomiting are typical extracardiac manifestations
of digoxin toxicity. Dialysis is an ineffective treatment for
intoxication, but the administration of digoxin immune Fab
is highly effective in life-threatening digoxin poisoning [74].
Nondihydropyridine calcium channel blockers (e.g., dil-
tiazem, verapamil) are an alternative treatment for patients
with contraindications to beta-blockers. Verapamil is more
negatively inotropic than diltiazem and must be used with
caution in patients with heart failure and after cardiac surgery
because of the increased incidence of conduction disorders.
The initial intravenous dose of diltiazem is 0.25mg/kg over
2min. If the response is inadequate, a second dose of
0.35mg/kg over 2min after 15min or a continuous infusion
of 10–15mg/h is administered. The usual intravenous dose
of verapamil is 2.5–5mg over 2min and may be followed by
5–10mg after 15–30min.
Dronedarone is an oral multichannel blocker, which
compared to amiodarone has a reduced lipophilicity and no
iodine components. It showed promising efficacy in multiple
trials [75, 76]; however, increased mortality in patients with
heart failure and risks of severe hepatotoxicity are of concern
[77–80]. Dronedarone has not been evaluated in critically ill
patients and is not yet available for intravenous administra-
tion, limiting its use in ICU settings.
The class Ic agents flecainide and propafenone are effi-
cacious in restoring sinus rhythm but are associated with
increased mortality in patients with structural heart disease
[81]. Therefore, they cannot be generally recommended in
ICU patients.
Vernakalant is a new antiarrhythmic agent that targets
atrial specific channels and has been approved for pharma-
cological cardioversion of AF of ≤7 days duration [76, 83–
85]. Vernakalant is given intravenously at an initial dose of
3mg/kg over 10min. If conversion fails, a second dose of
2mg/kg is given after 15min. Nausea, transient dysgeusia,
and sneezing are common side effects. Vernakalant has also
been studied after cardiac surgery, showing a conversion rate
of nearly 50%, with a low incidence of severe side effects
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Table 3: The CHA2DS2-VASc score: pointing system (modified
from [82]).
Risk factors Points
Chronic heart failure 1 pt
Hypertension 1 pt
Age 65–74 years 1 pt
Age >75 years 2 pts
Diabetes mellitus 1 pt
Stroke/TIA 2 pts
Vascular disease 1 pt
Sex (female) 1 pt
Legend: TIA: transient ischemic attack.
Table 4: The CHA2DS2-VASc score: theoretical risk of stroke/
thromboembolism per patient year without anticoagulation (modi-
fied from [82]).
Score Yearly TE rate
0 0%
1 1.3%
2 2.2%
3 3.2%
4 4.0%
5 6.7%
6 9.8%
7 9.6%
8 6.7%
9 15.2%
Legend: TE: thromboembolism.
(hypotension and complete atrioventricular block) [86]. So
far, data about the efficacy and safety of vernakalant in
critically ill patients are lacking.
3.7. Long-Term Treatment after Haemodynamic Stabilisation
3.7.1. Anticoagulation. AF can be complicated by thrombus
formation and embolisation. Approximately 25% of ischemic
strokes are caused by cardiogenic emboli, and almost half
of them occur in patients with AF [28]. The risk of these
complications is even higher in critically ill patients due
to ongoing inflammation and a procoagulatory state [87].
Thus, all patients with AF lasting for more than 48 hours
should be evaluated for anticoagulation. The scoring systems
for the stratification of cardioembolic risk are the CHADS
2
[88] and the newer CHA
2
DS
2
-VASc scores (Tables 3 and 4)
[89]. Although not validated for the setting of critically
illness, those scores may help clinicians in the decision about
antithrombotic therapy. Patients with no risk factors are at a
truly low risk and do not benefit from antithrombotic therapy
[89–92]. All other patients should receive a long-term anti-
coagulation therapy unless they have a markedly increased
bleeding risk [93]. We accomplish short-term anticoagula-
tion by an intravenous infusion of unfractionated heparin.
Without relevant bleeding, 10,000 IU per 24 hours is initiated
Table 5: The HAS-BLED score: pointing system.
Risk factors Points
Hypertension 1 pt
Abnormal renal/liver function 1 pt each
Stroke 1 pt
Bleeding (prior) 1 pt
Labile INR 1 pt
Elderly (age >65 years) 1 pt
Drugs and alcohol 1 pt each
Score ≥3 indicates high risk of major bleeding (>3.7%/y)
Legend: INR international normalized ratio.
6 hours postoperatively and is increased in steps of 2500–
5000 IE. Antifactor Xa activity is measured 6 hours after each
dose adjustment (target 0.3 to 0.7 IU/mL). Alternatively the
activated partial thromboplastin time (aPTT) may be used
(target 1.5–2.5 times the mean of the reference range). Long-
term anticoagulation with oral coumarins (e.g., warfarin,
phenprocoumon, acenocoumarol) is initiated when bleeding
has ceased and no invasive intervention is imminent (target
INR 2.0 and 3.0) [94, 95]. After an overlapping treatment,
heparin is stopped when the INR is in the target range
for two days. To assess the individual bleeding risk under
oral anticoagulation, the HAS-BLED score was proposed
(Table 5) [96, 97], although not validated for the ICU setting.
The new thrombin inhibitors (dabigatran) [98] and oral
factor Xa inhibitors (rivaroxaban [99], apixaban [100, 101])
cannot be recommended in critically ill patients at the current
time due to a lack of data in this particular population.
3.7.2. Further Management. Up to two-thirds of patients
experiencing a first episode of AF will spontaneously convert
into sinus rhythm within 24 hours [102]. Thus, maintenance
therapy with an antiarrhythmic drug after the first episode
of AF may often be omitted or discontinued before hos-
pital discharge [30]. An elective cardioversion is generally
recommended for patients with a recent onset AF as well
as in patients who remain symptomatic despite optimal rate
control. After discharge from the ICU selected patients may
benefit from catheter-based pulmonary vein isolation [38, 39,
41, 103], surgical treatment of AF (Cox Maze III procedure)
[104], or AV node ablation with permanent (biventricular)
pacing [105, 106] to reduce symptoms and increase functional
performance. A multidisciplinary approach in those cases is
necessary. In patients with contraindications to anticoagula-
tion therapy, surgical or percutaneous occlusion of the left-
atrial appendage is recommended [6, 107].
4. Conclusions
AF is the most common arrhythmia in the ICU, and it
can precipitate hypotension and heart failure. Despite recent
advances in the field and new published guidelines, the ther-
apeutic armamentarium for ICU patients remains limited.
ECV is the treatment of choice for patients with severe
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symptoms, but its efficacy is limited. Amiodarone, beta-
blockers, calcium channel blockers, and digoxin are used
most frequently, but their use is often complicated by adverse
effects. Newer drugs, such as dronedarone and vernakalant,
have not been generally introduced into the ICU setting yet
because they are not available intravenously, are contraindi-
cated with structural heart disease, or are disadvised due to
haemodynamic instability. New substanceswith high efficacy,
favourable haemodynamic effects, and a low risk profile are
urgently needed.
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